Literature DB >> 28124063

Nucleic acids as cofactors for factor XI and prekallikrein activation: Different roles for high-molecular-weight kininogen.

Ivan Ivanov, Ruhama Shakhawat, Mao-Fu Sun, S Kent Dickeson, Cristina Puy, Owen J T McCarty, Andras Gruber, Anton Matafonov, David Gailani1.   

Abstract

The plasma zymogens factor XI (fXI) and prekallikrein (PK) are activated by factor XIIa (fXIIa) during contact activation. Polyanions such as DNA and RNA may contribute to thrombosis and inflammation partly by enhancing PK and fXI activation. We examined PK and fXI activation in the presence of nucleic acids, and determine the effects of the cofactor high molecular weight kininogen (HK) on the reactions. In the absence of HK, DNA and RNA induced fXI autoactivation. Proteases known to activate fXI (fXIIa and thrombin) did not enhance this process appreciably. Nucleic acids had little effect on PK activation by fXIIa in the absence of HK. HK had significant but opposite effects on PK and fXI activation. HK enhanced fXIIa activation of PK in the presence of nucleic acids, but blocked fXI autoactivation. Thrombin and fXIIa could overcome the HK inhibitory effect on autoactivation, indicating these proteases are necessary for nucleic acid-induced fXI activation in an HK-rich environment such as plasma. In contrast to PK, which requires HK for optimal activation, fXI activation in the presence of nucleic acids depends on anion binding sites on the fXI molecule. The corresponding sites on PK are not necessary for PK activation. Our results indicate that HK functions as a cofactor for PK activation in the presence of nucleic acids in a manner consistent with classic models of contact activation. However, HK has, on balance, an inhibitory effect on nucleic acid-supported fXI activation and may function as a negative regulator of fXI activation.

Entities:  

Keywords:  Contact phase; coagulation factors; proteases

Mesh:

Substances:

Year:  2017        PMID: 28124063      PMCID: PMC5696789          DOI: 10.1160/TH16-09-0691

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  47 in total

1.  Factor XII inhibition reduces thrombus formation in a primate thrombosis model.

Authors:  Anton Matafonov; Philberta Y Leung; Adam E Gailani; Stephanie L Grach; Cristina Puy; Qiufang Cheng; Mao-Fu Sun; Owen J T McCarty; Erik I Tucker; Hiroaki Kataoka; Thomas Renné; James H Morrissey; Andras Gruber; David Gailani
Journal:  Blood       Date:  2014-01-09       Impact factor: 22.113

Review 2.  Medical device-induced thrombosis: what causes it and how can we prevent it?

Authors:  I H Jaffer; J C Fredenburgh; J Hirsh; J I Weitz
Journal:  J Thromb Haemost       Date:  2015-06       Impact factor: 5.824

3.  Effects of glycosaminoglycans on factor XI activation by thrombin.

Authors:  D Gailani; G J Broze
Journal:  Blood Coagul Fibrinolysis       Date:  1993-02       Impact factor: 1.276

Review 4.  Factor XI activation by thrombin and factor XIa.

Authors:  D Gailani; G J Broze
Journal:  Semin Thromb Hemost       Date:  1993       Impact factor: 4.180

Review 5.  Polyphosphate: an ancient molecule that links platelets, coagulation, and inflammation.

Authors:  James H Morrissey; Sharon H Choi; Stephanie A Smith
Journal:  Blood       Date:  2012-04-19       Impact factor: 22.113

6.  Factor XI activation by meizothrombin: stimulation by phospholipid vesicles containing both phosphatidylserine and phosphatidylethanolamine.

Authors:  P A von dem Borne; L O Mosnier; G Tans; J C Meijers; B N Bouma
Journal:  Thromb Haemost       Date:  1997-08       Impact factor: 5.249

Review 7.  Extracellular nucleic acids as novel alarm signals in the vascular system. Mediators of defence and disease.

Authors:  S Fischer; K T Preissner
Journal:  Hamostaseologie       Date:  2013-01-18       Impact factor: 1.778

8.  A comparison of the effects of factor XII deficiency and prekallikrein deficiency on thrombus formation.

Authors:  Yasin Kokoye; Ivan Ivanov; Qiufang Cheng; Anton Matafonov; S Kent Dickeson; Shauna Mason; Daniel J Sexton; Thomas Renné; Keith McCrae; Edward P Feener; David Gailani
Journal:  Thromb Res       Date:  2016-02-18       Impact factor: 3.944

9.  Defective thrombus formation in mice lacking coagulation factor XII.

Authors:  Thomas Renné; Miroslava Pozgajová; Sabine Grüner; Kai Schuh; Hans-Ulrich Pauer; Peter Burfeind; David Gailani; Bernhard Nieswandt
Journal:  J Exp Med       Date:  2005-07-11       Impact factor: 14.307

10.  Structural requirements for the procoagulant activity of nucleic acids.

Authors:  Julia Gansler; Miriam Jaax; Silke Leiting; Bettina Appel; Andreas Greinacher; Silvia Fischer; Klaus T Preissner
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

View more
  20 in total

1.  A kallikrein-targeting RNA aptamer inhibits the intrinsic pathway of coagulation and reduces bradykinin release.

Authors:  K-A Steen Burrell; J Layzer; B A Sullenger
Journal:  J Thromb Haemost       Date:  2017-08-02       Impact factor: 5.824

Review 2.  Neutrophils: back in the thrombosis spotlight.

Authors:  Denis F Noubouossie; Brandi N Reeves; Brian D Strahl; Nigel S Key
Journal:  Blood       Date:  2019-03-21       Impact factor: 22.113

3.  Factor XI contributes to myocardial ischemia-reperfusion injury in mice.

Authors:  Christina U Lorentz; Norah G Verbout; Zhiping Cao; Lijuan Liu; Monica T Hinds; Owen J T McCarty; Ivan Ivanov; Erik I Tucker; David Gailani; András Gruber
Journal:  Blood Adv       Date:  2018-01-23

4.  Red blood cell microvesicles activate the contact system, leading to factor IX activation via 2 independent pathways.

Authors:  Denis F Noubouossie; Michael W Henderson; Micah Mooberry; Anton Ilich; Patrick Ellsworth; Mark Piegore; Sarah C Skinner; Rafal Pawlinski; Ian Welsby; Thomas Renné; Maureane Hoffman; Dougald M Monroe; Nigel S Key
Journal:  Blood       Date:  2020-03-05       Impact factor: 22.113

5.  A synthetic heparin mimetic that allosterically inhibits factor XIa and reduces thrombosis in vivo without enhanced risk of bleeding.

Authors:  Rami A Al-Horani; Elsamani I Abdelfadiel; Daniel K Afosah; Shravan Morla; Jyothi C Sistla; Bassem Mohammed; Erika J Martin; Masahiro Sakagami; Donald F Brophy; Umesh R Desai
Journal:  J Thromb Haemost       Date:  2019-09-10       Impact factor: 5.824

Review 6.  Single-chain factor XII: a new form of activated factor XII.

Authors:  Ivan Ivanov; Anton Matafonov; David Gailani
Journal:  Curr Opin Hematol       Date:  2017-09       Impact factor: 3.284

7.  The Safety and Efficacy of Novel Agents Targeting Factors XI and XII in Early Phase Human Trials.

Authors:  Emma P DeLoughery; Sven R Olson; Cristina Puy; Owen J T McCarty; Joseph J Shatzel
Journal:  Semin Thromb Hemost       Date:  2019-06-19       Impact factor: 4.180

Review 8.  Plasma contact factors as therapeutic targets.

Authors:  Benjamin F Tillman; Andras Gruber; Owen J T McCarty; David Gailani
Journal:  Blood Rev       Date:  2018-04-12       Impact factor: 8.250

Review 9.  Inhibition of Factors XI and XII for Prevention of Thrombosis Induced by Artificial Surfaces.

Authors:  Benjamin Tillman; David Gailani
Journal:  Semin Thromb Hemost       Date:  2017-09-12       Impact factor: 4.180

Review 10.  An update on factor XI structure and function.

Authors:  Bassem M Mohammed; Anton Matafonov; Ivan Ivanov; Mao-Fu Sun; Qiufang Cheng; S Kent Dickeson; Chan Li; David Sun; Ingrid M Verhamme; Jonas Emsley; David Gailani
Journal:  Thromb Res       Date:  2017-10-10       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.